Controversial cancer patent upheld by EPO
20 November 2008
James Nurton, London
An EPO Technical Board of Appeal has maintained a controversial patent for diagnosing a predisposition for breast and ovarian cancer in amended form
The patent, number 699,754, was filed by Myriad Genetics, the University of Utah Research Foundation and the USA. It was published in 1996.
As approved by the Board, it covers diagnostic methods for detecting a predisposition...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial